CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention: A Review of the Clinical Impact of Treatment Duration

Last updated: August 18, 2017
Project Number: HT0001-000
Issue: 8
Result type: Report

Dual antiplatelet therapy (DAPT), the combination of a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) with acetylsalicylic acid (ASA), is routinely given following percutaneous coronary intervention (PCI) with stenting. This therapy aims to prevent stent thrombosis and other major cardiovascular adverse events associated with PCI. The choice of DAPT duration remains uncertain, although new evidence on the effect of longer treatment duration has recently become available. Selecting the treatment duration is an important decision in order to balance the benefits and harms of DAPT following PCI.

This project aims to summarize the evidence currently available on the comparative clinical effect of using shorter (6 to 12 months) versus longer (12 to 30 months) DAPT following PCI. Results from this project will inform reimbursement policies as well as clinical decisions on the use of P2Y12 inhibitors in patients who recently underwent a PCI.